General (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | 6 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Mar. 13, 2018 |
Jan. 08, 2018 |
Jan. 25, 2018 |
Dec. 31, 2016 |
Mar. 31, 2015 |
Jun. 30, 2018 |
Jun. 30, 2017 |
May 31, 2018 |
Mar. 09, 2018 |
Dec. 31, 2017 |
|
| General (Textual) | ||||||||||
| Incurred losses | $ (2,965) | $ (3,515) | ||||||||
| Accumulated losses | $ (97,017) | $ (93,702) | ||||||||
| Description of american depositary share | Each ADS represents 2 ordinary shares of the Company. | |||||||||
| Received net total of advance payment | $ 1,292 | |||||||||
| Aggregate ordinary shares | 3,333,336 | 400,000 | ||||||||
| Warrants to purchase shares | 2,500,002 | |||||||||
| Aggregate purchase price | $ 5,000 | |||||||||
| Warrants issued | 982,344 | |||||||||
| Warrants term | The warrants may be exercised after 6 months from the date of issuance for a period of five and a half years. | |||||||||
| March 2014 Financing [Member] | ||||||||||
| General (Textual) | ||||||||||
| Warrants issued | 98,234 | |||||||||
| Placement agent warrants [Member] | ||||||||||
| General (Textual) | ||||||||||
| Warrants to purchase shares | 166,667 | |||||||||
| ADS [Member] | ||||||||||
| General (Textual) | ||||||||||
| Aggregate ordinary shares | 6,666,672 | 200,000 | ||||||||
| Warrants to purchase shares | 5,000,004 | |||||||||
| Warrant exercise price | $ 2.00 | |||||||||
| ADS [Member] | Placement agent warrants [Member] | ||||||||||
| General (Textual) | ||||||||||
| Warrants to purchase shares | 333,334 | |||||||||
| Warrant exercise price | $ 2.00 | |||||||||
| Warrants term | five years | |||||||||
| CAD [Member] | ||||||||||
| General (Textual) | ||||||||||
| Received net total of advance payment | $ 1,650 | |||||||||
| Gebro Holding GmBH [Member] | ||||||||||
| General (Textual) | ||||||||||
| Description of distribution and supply agreement | Under the Distribution and Supply Agreement, the Company is entitled to €1.5 million upon execution of the agreement plus milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) €300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and €300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between €750 thousand and €1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between €300 thousand and up to €4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson | |||||||||
| Received first payment from Gebro | $ 2,200 | |||||||||
| CKD [Member] | ||||||||||
| General (Textual) | ||||||||||
| Upfront payment amount | $ 500 | |||||||||